![The Cancer Research Institute and The Lustgarten Foundation are excited to announce a new partnership, focused exclusively on supporting pancreatic cancer immunotherapy research. – Cancer Research Institute (CRI)](https://oncodaily.com/pub/uploads/2023/09/1695044041159.jpg)
Photo taken from Cancer Research Institute (CRI)/LinekdIn
Sep 19, 2023, 19:28
The Cancer Research Institute and The Lustgarten Foundation are excited to announce a new partnership, focused exclusively on supporting pancreatic cancer immunotherapy research. – Cancer Research Institute (CRI)
Quoting Cancer Research Institute (CRI) on LinkedIn:
“The Cancer Research Institute and The Lustgarten Foundation are excited to announce a new partnership, focused exclusively on supporting pancreatic cancer immunotherapy research. INSPIRE (Integrated Network for Supporting Pancreatic Cancer Immunotherapy Research Efforts) will encompass the established and ongoing adaptive platform trial, REVOLUTION, evaluating first-line chemo-immunotherapy treatment combinations for patients with metastatic pancreatic adenocarcinoma, and will also expand into new areas of pancreatic immunotherapy research. This next wave in immunotherapy research reflects a shared commitment to transforming pancreatic cancer into a curable disease. Discover: here.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023